心力衰竭的疾病修饰疗法：最新进展。

IF 7.3 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

QJM: An International Journal of Medicine Pub Date : 2025-03-01 DOI:10.1093/qjmed/hcaf060

Atsushi Tanaka, Koichi Node

{"title":"心力衰竭的疾病修饰疗法：最新进展。","authors":"Atsushi Tanaka, Koichi Node","doi":"10.1093/qjmed/hcaf060","DOIUrl":null,"url":null,"abstract":"There is currently limited evidence-based disease-modifying pharmacotherapy in patients with heart failure and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), forming an unmet clinical need in contemporary heart failure care. However, according to the finding from recent clinical trials with some medications such as finerenone and glucagon-like peptide-1 receptor agonist, a clinical concept of pharmacological therapy in patients with HFmrEF/HFpEF will be updated and upgraded. Based on recent evidences, we herein aim to discuss the possible roles of those medications in the HFmrEF/HFpEF therapy and propose an emerging pharmacological strategy for this population.","PeriodicalId":20806,"journal":{"name":"QJM: An International Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":7.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Disease modifying therapies in heart failure: an update.\",\"authors\":\"Atsushi Tanaka, Koichi Node\",\"doi\":\"10.1093/qjmed/hcaf060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There is currently limited evidence-based disease-modifying pharmacotherapy in patients with heart failure and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), forming an unmet clinical need in contemporary heart failure care. However, according to the finding from recent clinical trials with some medications such as finerenone and glucagon-like peptide-1 receptor agonist, a clinical concept of pharmacological therapy in patients with HFmrEF/HFpEF will be updated and upgraded. Based on recent evidences, we herein aim to discuss the possible roles of those medications in the HFmrEF/HFpEF therapy and propose an emerging pharmacological strategy for this population.\",\"PeriodicalId\":20806,\"journal\":{\"name\":\"QJM: An International Journal of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"QJM: An International Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/qjmed/hcaf060\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"QJM: An International Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/qjmed/hcaf060","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目前，在心力衰竭和轻度降低/保留射血分数（HFmrEF/HFpEF）患者中，循证改善疾病的药物治疗有限，形成了当代心力衰竭护理中未满足的临床需求。然而，根据最近一些药物如芬尼酮和胰高血糖素样肽-1受体激动剂的临床试验发现，HFmrEF/HFpEF患者的药物治疗的临床概念将会更新和升级。基于最近的证据，我们在此旨在讨论这些药物在HFmrEF/HFpEF治疗中的可能作用，并为这一人群提出一种新的药理学策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Disease modifying therapies in heart failure: an update.

There is currently limited evidence-based disease-modifying pharmacotherapy in patients with heart failure and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), forming an unmet clinical need in contemporary heart failure care. However, according to the finding from recent clinical trials with some medications such as finerenone and glucagon-like peptide-1 receptor agonist, a clinical concept of pharmacological therapy in patients with HFmrEF/HFpEF will be updated and upgraded. Based on recent evidences, we herein aim to discuss the possible roles of those medications in the HFmrEF/HFpEF therapy and propose an emerging pharmacological strategy for this population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

QJM: An International Journal of Medicine 医学-医学：内科

CiteScore

6.90

自引率

5.30%

发文量

263

审稿时长

4-8 weeks

期刊介绍： QJM, a renowned and reputable general medical journal, has been a prominent source of knowledge in the field of internal medicine. With a steadfast commitment to advancing medical science and practice, it features a selection of rigorously reviewed articles. Released on a monthly basis, QJM encompasses a wide range of article types. These include original papers that contribute innovative research, editorials that offer expert opinions, and reviews that provide comprehensive analyses of specific topics. The journal also presents commentary papers aimed at initiating discussions on controversial subjects and allocates a dedicated section for reader correspondence. In summary, QJM's reputable standing stems from its enduring presence in the medical community, consistent publication schedule, and diverse range of content designed to inform and engage readers.